Repository logo
 
Publication

Treatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological review

2016-03Journal article Restricted access
Simple item page
dc.contributor.authorCampos, Carlos
dc.contributor.authorRocha, Nuno
dc.contributor.authorVieira, Renata Teles
dc.contributor.authorRocha, Susana A
dc.contributor.authorTelles-Correia, Diogo
dc.contributor.authorPaes, Flávia
dc.contributor.authorYuan, Tifei
dc.contributor.authorNardi, Antonio Egidio
dc.contributor.authorArias-Carrión, Oscar
dc.contributor.authorMachado, Sergio
dc.contributor.authorCaixeta, Leonardo
dc.date.accessioned2017-01-26T17:09:52Z
dc.date.available2017-01-26T17:09:52Z
dc.date.issued2016-03
dc.description.abstractThe growing and aging population has contributed to the increased prevalence of Alzheimer's disease (AD) and other types of dementia in the world. AD is a progressive and degenerative brain disease with an onset characterized by episodic memory impairments, although progressive deficits can be observed in several domains including language, executive functions, attention and working memory. The relationship between cognitive impairments and the topography and progression of brain neuropathology is well established. The pathophysiologic mechanisms and processes that underline the course of cognitive and clinical decline have been the theoretical support for the development of pharmacological treatments for AD. Cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartate (NMDA) antagonists are the main drugs used in the management of global cognitive impairment and several studies also explore the effects of both in specific cognitive measures. Recent research trends also examine the effects of combination therapy using both compounds. This review aims to update practical recommendations for the treatment of global cognitive functioning and specific neurocognitive deficits in AD using ChEIs, NMDA antagonists and combination therapy with both drugs.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10400.22/9465
dc.identifier.urihttp://hdl.handle.net/10400.22/9465
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectAlzheimer Diseasept_PT
dc.subjectCholinesterase Inhibitorspt_PT
dc.subjectCognition Disorderspt_PT
dc.subjectHumanspt_PT
dc.subjectN-Methylaspartatept_PT
dc.titleTreatment of Cognitive Deficits in Alzheimer's disease: A psychopharmacological reviewpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPage2-12pt_PT
oaire.citation.titlePsychiatria Danubinapt_PT
oaire.citation.volume28pt_PT
person.familyNameCampos
person.familyNameRocha
person.givenNameCarlos
person.givenNameNuno
person.identifier192266
person.identifier.ciencia-idB518-6A52-D50F
person.identifier.ciencia-idAE16-A494-5F8B
person.identifier.orcid0000-0002-5966-4050
person.identifier.orcid0000-0002-3139-2786
person.identifier.ridM-9821-2013
person.identifier.scopus-author-id56567519500
person.identifier.scopus-author-id32867975300
rcaap.rightsclosedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationf9744770-c154-483e-b271-b58d1089d55f
relation.isAuthorOfPublication9e940914-601a-4978-8d5b-74e5ade7ada7
relation.isAuthorOfPublication.latestForDiscovery9e940914-601a-4978-8d5b-74e5ade7ada7

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ART_NunoRocha_TO_2016.pdf
Size:
216.24 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESS - TO - Artigos
ISCAP - Gestão - Artigos